Document is current
Any future updates will be listed below
-
Authors
Rastogi, Reena G. https://orcid.org/0009-0005-7864-0950
Santiago, Jason A.
Chang, Alicia https://orcid.org/0009-0002-4512-2864
Mama, Eden https://orcid.org/0009-0000-5076-7427
Stark-Inbar, Alit https://orcid.org/0000-0001-6434-6447
Ironi, Alon https://orcid.org/0000-0002-3992-4978
Towne, Alan R. https://orcid.org/0000-0003-4263-7336
Werner, Klaus https://orcid.org/0000-0002-9314-8076
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct07336056 at ClinicalTrials.govDocuments that mention this clinical trial
A Real-World Evidence Study on US Patients Demonstrating Safety of High-Frequency Use of the Remote Electrical Neuromodulation (REN) Wearable Device for Migraine Treatment
https://doi.org/10.1007/s40122-026-00828-9
-
Funding
Funding for this research was provided by:
Theranica
- License Information
-
More Information
Article History
Received: 13 January 2026
Accepted: 24 February 2026
First Online: 26 March 2026
Declarations
:
: Reena G. Rastogi: Advisory board for Theranica. Jason A. Santiago: Promotional Speaker for Theranica, Pfizer. Alicia Chang: No Conflict of interest. Eden Mama: Theranica employee. Alit Stark-Inbar: Theranica employee. Alon Ironi: Employee and stockholder at Theranica. Alan R. Towne: Received grant funding from DOD. Klaus Werner: Advisory board for Theranica.
: The study was approved by the WIRB-Copernicus Group Institutional Review Board (WCG IRB; Tracking Number 20260001) and performed in accordance with the Helsinki Declaration of 1964 and its later amendments. During registration in the REN mobile application, patients provided informed consent for the collection and research of de-identified data and demographic information (age and sex).
